TransTech Pharma Selects Genedata to Enhance High Throughput Screening Analysis
News Dec 14, 2005
Genedata has announced that TransTech Pharma has signed a multi-year license for high throughput screening analysis software Genedata Screener®.
Scientists at TransTech Pharma will use Screener to enhance their efforts to develop small molecules as therapeutics for treating human diseases.
"We sought a solution that could be deployed seamlessly with our drug discovery workflow," explained Dr. Robert Rothlein, Senior VP Biology at TransTech Pharma, Inc.
Screener has been integrated with TransTech Pharma’s IT and screening infrastructure. It will automate data quality evaluation and standardize the analysis of compound bioactivity.
Dr. Robert added, "Genedata’s solution saves time and cost in the lead discovery workflow."
"Screener’s modular design and open architecture were important factors in the success of our deployment at TransTech Pharma," says Dr. Michael Lindemann, Business Head Genedata Screener.
TransTech Pharma have developed a highly parallel and integrated Translational Technology® that links together drug design, synthesis and screening.
"We are able to support and enhance this workflow without resource-intensive customization of the Screener platform."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019